Advanced search
Publication Cover
International Journal of Neuroscience Volume 16, 1982 - Issue 3-4
Submit an article Journal homepage
9
Views
42
CrossRef citations to date
0
Altmetric
Original Article

Oral Administration of Chronic Physostigmine does not Improve Cognitive or Mnesic Performances in Alzheimer's Presenile Dementia

C. Caltagirone Institute of Neurology, Catholic University, Rome, Italy
,
G. Gainotti Institute of Neurology, Catholic University, Rome, ItalyView further author information
&
C. Masullo Institute of Neurology, Catholic University, Rome, ItalyView further author information
Pages 247-249 | Published online: 07 Jul 2009

Citations (42)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Edward J. Calabrese. (2008) Alzheimer's Disease Drugs: An Application of the Hormetic Dose-Response Model. Critical Reviews in Toxicology 38:5, pages 419-451.
Read now
Michael Rainer & Hermann AM Mucke. (1998) Twenty years of cholinergic intervention in Alzheimer's disease: A tale of disappointment and ultimate confidence. International Journal of Psychiatry in Clinical Practice 2:3, pages 173-179.
Read now
Miroljub Popović, Natalija Popović, Katica Jovanova-Nešć, Dubravko Bokonjić, Silva Dobrić, Vladimir S. Kostić & Nedeljko Rosić. (1997) Effect of Physostigmine and Verapamil on Active Avoidance in an Experimental Model of Alzheimer's Disease. International Journal of Neuroscience 90:1-2, pages 87-97.
Read now
D. D. Cardenas, A. McLean, L. Farrell-roberts, L. Baker, M. Brooke & J. Haselkorn. (1994) Oral physostigmine and impaired memory in adults with brain injury. Brain Injury 8:7, pages 579-587.
Read now
Alvin McLean, Karen M. Stanton, Diana D. Cardenas & Donna B. Bergerud. (1987) Memory training combined with the use of oral physostigmine. Brain Injury 1:2, pages 145-159.
Read now
C. Caltagirone, A. Albanese, G. Gainotti & C. Masullo. (1983) Acute Administration of Individual Optimal Dose of Physostigmine Fails to Improve Mnesic Performances in Alzheimers Presenile Dementia. International Journal of Neuroscience 18:1-2, pages 143-147.
Read now

Articles from other publishers (36)

Brian RobinsonBrian Robinson. 2023. The Calabar Bean and its Alkaloids. The Calabar Bean and its Alkaloids 169 224 .
Edward J. Calabrese. (2008) Hormesis and medicine. British Journal of Clinical Pharmacology 66:5, pages 594-617.
Crossref
Pankaj D. Rege & Francis Johnson. (2003) Application of Vicarious Nucleophilic Substitution to the Total Synthesis of dl -Physostigmine . The Journal of Organic Chemistry 68:16, pages 6133-6139.
Crossref
João M JMC Coelho Filho & Jacqueline Birks. (2001) Physostigmine for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews.
Crossref
Jair C. Soares & Samuel Gershon. (1994) Advances in the pharmacotherapy of Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience 244:5, pages 261-271.
Crossref
P.B.S. Clarke, M. Reuben & H. El-Bizri. (1994) Blockade of nicotinic responses by physostigmine, tacrine and other cholinesterase inhibitors in rat striatum. British Journal of Pharmacology 111:3, pages 695-702.
Crossref
Anthony Wetherell. (1992) Effects of physostigmine on stimulus encoding in a memory-scanning task. Psychopharmacology 109:1-2, pages 198-202.
Crossref
Martin Sarter, Jim Hagan & Paul Dudchenko. (1992) Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I. Psychopharmacology 107:2-3, pages 144-159.
Crossref
Diana D. Cardenas & Alvin McLeanJrJr. (1992) Psychopharmacologic Management of Traumatic Brain Injury. Physical Medicine and Rehabilitation Clinics of North America 3:2, pages 273-290.
Crossref
Cesare Mondadori, Hugo Buerki, Juergen Borkowski, Elisabeth Radeke, Thomas Ducret & Alfred Glatt. (1992) CGS 5649 B, a new compound, reverses age-related cognitive dysfunctions in rats. Behavioral and Neural Biology 57:2, pages 149-156.
Crossref
L. Tune, J. Brandt, J. J. Frost, G. Harris, H. Mayberg, C. Steele, A. Burns, J. Sapp, M. F. Folstein, H. N. Wagner & G. D. Pearlson. (2007) Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography. Acta Psychiatrica Scandinavica 83:S366, pages 61-65.
Crossref
Robert E. Becker, Pamela Moriearty & Latha Unni. 1991. Cholinergic Basis for Alzheimer Therapy. Cholinergic Basis for Alzheimer Therapy 263 296 .
Pow F. Kwo-On-Yuen, Ronald Mandel, Andrew D. Chen & Leon J. Thal. (1990) Tetrahydroaminoacridine improves the spatial acquisition deficit produced by nucleus basalis lesions in rats. Experimental Neurology 108:3, pages 221-228.
Crossref
Massimo Pomponi, E. Giacobini & M. Brufani. (2013) Present state and future development of the therapy of Alzheimer disease. Aging Clinical and Experimental Research 2:2, pages 125-153.
Crossref
M. Sarter, J. P. Bruno & P. Dudchenko. (1990) Activating the damaged basal forebrain cholinergic system: tonic stimulation versus signal amplification. Psychopharmacology 101:1, pages 1-17.
Crossref
. (2016) Notices. Journal of Geriatric Psychiatry and Neurology 3:2, pages 119-120.
Crossref
Lindy E. Harrell, Richard S. Jope, Janet Falgout, Ross Callaway, Carol Avery, Mary Spiers, Dano Leli, Donna Morere & James H. HalseyJrJr. (2015) Biological and Neuropsychological Characterization of Physostigmine Responders and Nonresponders in Alzheimer's Disease. Journal of the American Geriatrics Society 38:2, pages 113-122.
Crossref
Seiichi Takano & Kunio Ogasawara. 1990. 225 251 .
Christopher J. Patterson. 1990. Preventing Disease. Preventing Disease 150 167 .
Stephen Vida, Louise GauthierSerge Gauthier. (1989) Canadian Collaborative Study of Tetrahydroaminoacridine (THA) and Lecithin Treatment of Alzheimer's Disease: Effect on Mood. The Canadian Journal of Psychiatry 34:3, pages 165-170.
Crossref
D.W. Molloy & R.D.T. Cape. (1989) Acute effects of oral pyridostigmine on memory and cognitive function in SDAT. Neurobiology of Aging 10:2, pages 199-204.
Crossref
Satu M. Somani. (2006) Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. Biopharmaceutics & Drug Disposition 10:2, pages 187-203.
Crossref
Leon J. Thal, David M. Masur, Alan D. Blau, Paula A. Fuld & Melville R. Klauber. (1989) Chronic Oral Physostigmine Without Lecithin Improves Memory in Alzheimer's Disease. Journal of the American Geriatrics Society 37:1, pages 42-48.
Crossref
R. Becker, E. Giacobini, R. Elble, M. McIlhany & K. Sherman. (1988) POTENTIAL PHARMACOTHERAPY OF ALZHEIMER DISEASE. A COMPARISON OF VARIOUS FORMS OF PHYSOSTIGMINE ADMINISTRATION. Acta Neurologica Scandinavica 77, pages 19-32.
Crossref
. 1988. Memory Disorders in Clinical Practice. Memory Disorders in Clinical Practice 219 268 .
Robert E. Becker & Ezio Giacobini. (1988) Mechanisms of cholinesterase inhibition in senile dementia of the alzheimer type: Clinical, pharmacological, and therapeutic aspects. Drug Development Research 12:3-4, pages 163-195.
Crossref
L. Gustafson, L. Edvinsson, N. Dahlgren, B. Hagberg, J. Risberg, I. Rosén & H. Fernö. (1987) Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG. Psychopharmacology 93:1, pages 31-35.
Crossref
Yaakov Stern, Mary Sano & Richard Mayeux. (2004) Effects of oral physostigmine in Alzheimer's disease. Annals of Neurology 22:3, pages 306-310.
Crossref
Maurice Dysken. (1987) A Review of Recent Clinical Trials in the Treatment of Alzheimer's Dementia. Psychiatric Annals 17:3, pages 178-191.
Crossref
S. Gauthier, R. Leblanc, R. Quirion, G. Carlsson, M. Beaulieu, R. Bouchard, D. Dastoor, F. Ervin, L. Gauthier, M. Gauvin, J. Henry, R. Palmour & Y. Robitaille. (2015) Transmitter-replacement Therapy in Alzheimer's Disease Using Intracerebroventricular Infusions of Receptor Agonists. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 13:S4, pages 394-402.
Crossref
Arthur S. Schwartz & Elizabeth V. Kohlstaedt. (1986) Physostigmine effects in Alzheimer's disease: Relationship to dementia severity. Life Sciences 38:11, pages 1021-1028.
Crossref
Aman U. KhanAman U. Khan. 1986. Clinical Disorders of Memory. Clinical Disorders of Memory 105 119 .
Aman U. KhanAman U. Khan. 1986. Clinical Disorders of Memory. Clinical Disorders of Memory 67 87 .
Aman U. KhanAman U. Khan. 1986. Clinical Disorders of Memory. Clinical Disorders of Memory 239 256 .
Richard C. Mohs, Bonnie M. Davis, Blaine S. Greenwald, A. A. Mathé, Celeste A. Johns, Thomas B. Horvath & Kenneth L. Davis. (1985) Clinical Studies of the Cholinergic Deficit in Alzheimer's Disease. Journal of the American Geriatrics Society 33:11, pages 749-757.
Crossref
Fred M. Hershenson & John G. Marriott. 1984. 31 40 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.